Sigyn Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OTC.Pink
Brio Capital Master Fund Ltd. and Brio Capital Management LLC have filed an amended Schedule 13G, reporting a 9.99% beneficial ownership stake in SIGYN THERAPEUTICS, INC. as of December 31, 2025.
OTC.Pink
SCHEDULE 13G/A: Brio Capital Master Fund Ltd. and Brio Capital Management LLC Maintain 9.99% Stake in Sigyn Therapeutics
Brio Capital Master Fund Ltd. and Brio Capital Management LLC have filed an amended Schedule 13G, reporting a 9.99% beneficial ownership stake in Sigyn Therapeutics, Inc., totaling 158,932 shares as of November 19, 2024.